Triplet takes the lead.

While Abraxane added to gemcitabine didn’t lead to any exciting advancements in the treatment of advanced cholangiocarcinoma, adding it to the standard duo of gem and cisplatin resulted in the most promising results seen yet. This single-arm phase 2 trial reports unprecedented median progression-free (12 months) and overall (19 months) survival times among patients with advanced cholangio receiving upfront combo therapy with gem/cis + Abraxane. | Shroff, JAMA Oncol 2019